EP Patent

EP2762135A1 — Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

Assigned to Sanofi SA · Expires 2014-08-06 · 12y expired

What this patent protects

This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and / or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3).

USPTO Abstract

This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and / or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3).

Drugs covered by this patent

Patent Metadata

Patent number
EP2762135A1
Jurisdiction
EP
Classification
—
Expires
2014-08-06
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.